TITLE

Platelet Adhesiveness: Methodology for Testing in Humans

AUTHOR(S)
Jacobi, E.; Bremer, G.; Richter, O.
PUB. DATE
April 1981
SOURCE
Angiology;Apr1981, Vol. 32 Issue 4, p243
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Platelets play an important role in the pathogenesis of early thrombus formation and might even be involved in initiating the process of atherosclerosis. Various platelet adhesiveness test methods are discussed. Results of an in vitro test in about 600 patients with various diseases are given. The effect from anti-platelet drugs like dipyridamole and acetyl salicylic acid in preventing increase of platelet adhesiveness due to a biologic stressor are compared with those obtained with isoxsuprine. Platelets play an important role in the pathogenesis of early thrombus formation. Platelets might also be involved in initiating the process of atherosclerosis. Therefore, it is understandable that various test methods to measure platelet behavior has been developed.
ACCESSION #
16394641

 

Related Articles

  • Ticlid/Plavix formulary evaluation.  // Drug Utilization Review;Dec2001, Vol. 17 Issue 12, p1 

    Presents information on platelet aggregation inhibitors, Clopidogrel (Plavix) from Bristol-Myers-Squibb/Sanofi and Ticlopidine (Ticlid) from Roche. Mechanism of action and pharmacokinetics of the drugs; Dosage and indications for use of the drugs; Safety and clinical trials of the drugs.

  • Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. Awidi, Abdalla; Saleh, Akram; Dweik, Manar; Kailani, Baraah; Abu-Fara, Mohammed; Nabulsi, Rinad; Bener, Abdulbari // Heart & Vessels;Sep2011, Vol. 26 Issue 5, p516 

    Acetyl salicylic acid (ASA) and clopidogrel are extensively used in the prevention of cardiovascular disease. However, the responsiveness to ASA treatment may vary among individuals. This study was conducted to investigate the profile and prevalence of ASA resistance in cardiac patients. From...

  • Sibrafiban. Dooley, M.; Goa, K.L. // Drugs;Feb1999, Vol. 57 Issue 2, p225 

    â–´ Sibrafiban is the orally administered, nonpeptide, double-prodrug of Ro 44-3888 which is a selective glycoprotein IIb/IIIa receptor antagonist. It is currently undergoing clinical trials for secondary prevention of cardiac events in patients stabilised after acute coronary syndromes....

  • Editorial [Hot Topic:The Search for Novel Anti-Thrombotic Drug Targets (Executive Editor: Dermot Cox)]. Cox, Dermot // Current Pharmaceutical Design;Sep2007, Vol. 13 Issue 26, p2638 

    Atherosclerosis is the leading cause of death in the Western world and anti-thrombotic therapy plays a key role in the management of this disease. However, despite the importance of platelets in the disease process there has been little progress in developing novel anti-thrombotic agents....

  • The Basis of Platelets.  // Drugs;2010 Supplement 1, Vol. 70, p9 

    No abstract available.

  • Identification of Potential Predisposition to Clinical Atherosclerosis: A Clinical Concept Based on Integration of Significant Blood Parameters with Platelet Aggregation Scores. Kaplan, Alexander; Kaplan, Svetlana; Marcoe, Karen F.; Sauvage, Lesler R.; Hammond, William P. // Clinical & Applied Thrombosis/Hemostasis;Jul1997, Vol. 3 Issue 3, p174 

    We sought to develop a predictive method, based on the integration of blood parameters found to be significantly associated with thrombosis and progression of atherosclerosis, that would be more accurate than primary reliance on elevation of separate risk factors. The study involved 1,034 male...

  • Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Attallah, N.; Yassine, L.; Fisher, K.; Yee, J. // Clinical Nephrology;2005, Vol. 64 Issue 6, p412 

    Background: Bleeding risk is increased in renal failure due to impaired platelet adhesiveness. Patients who undergo percutaneous coronary intervention (PCI) are given multiple antiplatelet agents that increase that risk. We retrospectively tested the hypothesis that chronic kidney disease (CKD)...

  • Effects of Atenolol and Propranolol on Platelet Aggregation in Moderate Essential Hypertension: Randomized Crossover Trial. Punda, Ante; Polić, Stojan; Rumboldt, Zvonko; Bagatin, Jugoslav; Marković, Vinko; Lukin, Ajvor // Croatian Medical Journal;2005, Vol. 46 Issue 2, p219 

    Compares the effects of a selective beta-blocker atenolol and a nonselective beta-blocker propanolol on platelet aggregation. Role of platelet aggregation and arterial hypertension in the development of atherosclerosis; Methodology of the study; Discussion on the results of the study.

  • Biological efficacy of low versus medium dose aspirin after coronary surgery: results from a randomized trial [NCT00262275]. Lim, Eric; Cornelissen, Jacqueline; Routledge, Tom; Ali, Ayyaz; Kirtland, Stephen; Sharples, Linda; Sheridan, Kate; Bellm, Sarah; Munday, Helen; Large, Stephen // BMC Medicine;2006, Vol. 4, p12 

    Background: The beneficial effect of aspirin after coronary surgery is established; however, a recent study reported the inability of low doses (100 mg) to inhibit postoperative platelet function. We conducted a double-blind randomised trial to establish the efficacy of low dose aspirin and to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics